Brief: Eiger Biopharmaceuticals Reports First Quarter Loss Of $0.52 Per Share
11/05/2023 21:32
May 11 (Reuters) - Eiger BioPharmaceuticals Inc
EIGR.O :
* EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2023
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
* EIGER BIOPHARMACEUTICALS INC - QTRLY LOSS PER SHARE $ 0.52
* EIGER BIOPHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.52
Source text for Eikon: ID:nPn61wrDLa
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview